Publication: Ataluren use in patients with nonsense mutation Duchenne muscular dystrophy (nmDMD): Patient demographics and characteristics from the STRIDE Registry
This research article, published in the Journal ofComparative Effectiveness Research, outlines the initial demographics and baseline characteristics of patients enrolled in STRIDE, an observational registry of nmDMD patients receiving a mutation-specific DMD therapy
The demographics and baseline characteristics of the Strategic Targeting of Registries and International Database of Excellence (STRIDE) Registry population and the principal interim safety results (data cut-off: 9 July 2018) is presented
Muntoni F, Desguerre I, Guglieri M, et al. J Comp Eff Res. 2019;8(14):1187–1200
Once registered, you will be able to view the abstract and be provided the DOI and PubMed links for this publication.
▼ Ataluren is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system. Adverse events should also be reported to PTC at firstname.lastname@example.org.
Registration conditions differ internationally, and prescribing information may vary depending on local approval in each country. The European Summary of Product Characteristics for ataluren is available here. Please refer to your local country guidance for more information.
Register now to unlock the content
Register now to access the content on this page
If not, register below
MED-ALL-DMD-2200190 | August 2022
Sign in or register to access exclusive content on this site